Increased mitochondrial emission of reactive oxygen species and calpain activation are required for doxorubicin-induced cardiac and skeletal muscle myopathy

Journal of Physiology

Volumn 593, Issue 8, 2015, Pages 2017-2036

  Min, Kisuk ^a   Kwon, Oh Sung ^a   Smuder, Ashley J ^a   Wiggs, Michael P ^a   Sollanek, Kurt J ^a   Christou, Demetra D ^a   Yoo, Jeung Ki ^a   Hwang, Moon Hyon ^a   Szeto, Hazel H ^b   Kavazis, Andreas N ^c   Powers, Scott K ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; CALPAIN; CASPASE 3; DOXORUBICIN; N (4 FLUOROPHENYLSULFONYL)VALYLLEUCINAL; REACTIVE OXYGEN METABOLITE; SS 31; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CONTRACTILE DYSFUNCTION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; HEART MUSCLE; HEART MUSCLE CELL; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; MUSCLE ATROPHY; MUSCLE DISEASE; MYOPATHY; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; RAT; SKELETAL MUSCLE; ANIMAL; CARDIAC MUSCLE; CHEMICALLY INDUCED; DRUG EFFECTS; HEART; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; CALPAIN; DOXORUBICIN; FEMALE; HEART; MITOCHONDRIA; MUSCLE, SKELETAL; MUSCULAR DISEASES; MYOCARDIUM; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

EID: 84927697865     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2014.286518     Document Type: Article

References (59)

1. 2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 119, 573-581.
2. Anderson EJ & Neufer PD (2006). Type II skeletal myofibers possess unique properties that potentiate mitochondrial H(2)O(2) generation. Am J Physiol Cell Physiol 290, C844-C851.
3. Anisimov VN, Bakeeva LE, Egormin PA, Filenko OF, Isakova EF, Manskikh VN, Mikhelson VM, Panteleeva AA, Pasyukova EG, Pilipenko DI, Piskunova TS, Popovich IG, Roshchina NV, Rybina OY, Saprunova VB, Samoylova TA, Semenchenko AV, Skulachev MV, Spivak IM, Tsybul'ko EA, Tyndyk ML, Vyssokikh MY, Yurova MN, Zabezhinsky MA & Skulachev VP (2008). Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging pro-gram. 5. SkQ1 prolongs lifespan and prevents development of traits of senescence. Biochemistry (Mosc) 73, 1329-1342.
4. Berthiaume JM & Wallace KB (2007). Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 23, 15-25.
5. Birk AV, Chao WM, Bracken C, Warren JD & Szeto HH (2014). Targeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesis. Br J Pharmacol 171, 2017-2028.
6. Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD & Szeto HH (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 24, 1250-1261.
7. Campos EC, O'Connell JL, Malvestio LM, Romano MM, Ramos SG, Celes MR, Prado CM, Simoes MV & Rossi MA (2011). Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. Eur J Pharmacol 670, 541-553.
8. Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA & Oliveira PJ (2014). Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34, 106-135.
9. Chandran K, Aggarwal D, Migrino RQ, Joseph J, McAllister D, Konorev EA, Antholine WE, Zielonka J, Srinivasan S, Avadhani NG & Kalyanaraman B (2009). Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-Q. Biophys J 96, 1388-1398.
10. Childs AC, Phaneuf SL, Dirks AJ, Phillips T & Leeuwenburgh C (2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 62, 4592-4598.
11. Dai DF, Chiao YA, Marcinek DJ, Szeto HH & Rabinovitch PS (2014). Mitochondrial oxidative stress in aging and healthspan. Longev Healthspan 3, 6.
12. Davies KJ & Doroshow JH (1986). Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. J Biol Chem 261, 3060-3067.
13. Doroshow JH (1983). Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 43, 4543-4551.
14. Doughan AK & Dikalov SI (2007). Mitochondrial redox cycling of mitoquinone leads to superoxide production and cellular apoptosis. Antioxid Redox Signal 9, 1825-1836.
15. Elliott P (2006). Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 33, S2-S7.
16. Ferrans VJ (1978). Overview of cardiac pathology in relation to anthracycline cardiotoxicity. Cancer Treat Rep 62, 955-961.
17. Fukiage C, Azuma M, Nakamura Y, Tamada Y, Nakamura M & Shearer TR (1997). SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: amelioration of cataract in cultured rat lenses. Biochim Biophys Acta 1361, 304-312.
18. Gilliam LA, Ferreira LF, Bruton JD, Moylan JS, Westerblad H, St Clair DK & Reid MB (2009). Doxorubicin acts through tumor necrosis factor receptor subtype 1 to cause dysfunction of murine skeletal muscle. J Appl Physiol 107, 1935-1942.
19. Gilliam LA, Fisher-Wellman KH, Lin CT, Maples JM, Cathey BL & Neufer PD (2013). The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle. Free Radic Biol Med 65, 988-996.
20. Gilliam LA, Moylan JS, Ann Callahan L, Sumandea MP & Reid MB (2011). Doxorubicin causes diaphragm weakness in murine models of cancer chemotherapy. Muscle Nerve 43, 94-102.
21. Goll DE, Thompson VF, Li H, Wei W & Cong J (2003). The calpain system. Physiol Rev 83, 731-801.
22. Goormaghtigh E, Huart P, Brasseur R & Ruysschaert JM (1986). Mechanism of inhibition of mitochondrial enzymatic complex I-III by adriamycin derivatives. Biochim Biophys Acta 861, 83-94.
23. Goormaghtigh E, Huart P, Praet M, Brasseur R & Ruysschaert JM (1990). Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys Chem 35, 247-257.
24. Hayward R, Hydock D, Gibson N, Greufe S, Bredahl E & Parry T (2013). Tissue retention of doxorubicin and its effects on cardiac, smooth, and skeletal muscle function. J Physiol Biochem 69, 177-187.
25. Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, Mutharasan RK, Naik TJ & Ardehali H (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest 124, 617-630.
26. Jeyaseelan R, Poizat C, Wu HY & Kedes L (1997). Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes. J Biol Chem 272, 5828-5832.
27. Kang YJ, Chen Y, Yu A, Voss-McCowan M & Epstein PN (1997). Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity. J Clin Invest 100, 1501-1506.
28. Kavazis AN, Smuder AJ, Min K, Tumer N & Powers SK (2010). Short-term exercise training protects against doxorubicin-induced cardiac mitochondrial damage independent of HSP72. Am J Physiol Heart Circ Physiol 299, H1515-H1524.
29. Kupina NC, Nath R, Bernath EE, Inoue J, Mitsuyoshi A, Yuen PW, Wang KK & Hall ED (2001). The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J Neurotrauma 18, 1229-1240.
30. Lim CC, Zuppinger C, Guo X, Kuster GM, Helmes M, Eppenberger HM, Suter TM, Liao R & Sawyer DB (2004). Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes. J Biol Chem 279, 8290-8299.
31. McClung JM, Kavazis AN, DeRuisseau KC, Falk DJ, Deering MA, Lee Y, Sugiura T & Powers SK (2007). Caspase-3 regulation of diaphragm myonuclear domain during mechanical ventilation-induced atrophy. Am J Respir Crit Care Med 175, 150-159.
32. Messer JI, Jackman MR & Willis WT (2004). Pyruvate and citric acid cycle carbon requirements in isolated skeletal muscle mitochondria. Am J Physiol Cell Physiol 286, C565-C572.
33. Min K, Smuder AJ, Kwon OS, Kavazis AN, Szeto HH & Powers SK (2011). Mitochondrial-targeted antioxidants protect skeletal muscle against immobilization-induced muscle atrophy. J Appl Physiol 111, 1459-1466.
34. Montaigne D, Marechal X, Preau S, Baccouch R, Modine T, Fayad G, Lancel S & Neviere R (2011). Doxorubicin induces mitochondrial permeability transition and contractile dysfunction in the human myocardium. Mitochondrion 11, 22-26.
35. Muller AL & Dhalla NS (2012). Role of various proteases in cardiac remodeling and progression of heart failure. Heart Fail Rev 17, 395-409.
36. Myers CE, McGuire WP, Liss RH, Ifrim I, Grotzinger K & Young RC (1977). Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197, 165-167.
37. Nelson WB, Smuder AJ, Hudson MB, Talbert EE & Powers SK (2012). Cross-talk between the calpain and caspase-3 proteolytic systems in the diaphragm during prolonged mechanical ventilation. Crit Care Med 40, 1857-1863.
38. Pfeiffer K, Gohil V, Stuart RA, Hunte C, Brandt U, Greenberg ML & Schagger H (2003). Cardiolipin stabilizes respiratory chain supercomplexes. J Biol Chem 278, 52873-52880.
39. Powers SK, Hudson MB, Nelson WB, Talbert EE, Min K, Szeto HH, Kavazis AN & Smuder AJ (2011a). Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness. Crit Care Med 39, 1749-1759.
40. Powers SK, Kavazis AN & McClung JM (2007). Oxidative stress and disuse muscle atrophy. J Appl Physiol (1985) 102, 2389-2397.
41. Powers SK, Smuder AJ & Criswell DS (2011b). Mechanistic links between oxidative stress and disuse muscle atrophy. Antioxid Redox Signal 15, 2519-2528.
42. Powers SK, Smuder AJ & Judge AR (2012a). Oxidative stress and disuse muscle atrophy: cause or consequence? Curr Opin Clin Nutr Metab Care 15, 240-245.
43. Powers SK, Wiggs MP, Duarte JA, Zergeroglu AM & Demirel HA (2012b). Mitochondrial signaling contributes to disuse muscle atrophy. Am J Physiol Endocrinol Metab 303, E31-E39.
44. Reid MB (2008). Free radicals and muscle fatigue: Of ROS, canaries, and the IOC. Free Radic Biol Med 44, 169-179.
45. Saido TC, Sorimachi H & Suzuki K (1994). Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 8, 814-822.
46. Segal SS, White TP & Faulkner JA (1986). Architecture, composition, and contractile properties of rat soleus muscle grafts. Am J Physiol Cell Physiol 250, C474-C479.
47. Sharma AK & Rohrer B (2004). Calcium-induced calpain mediates apoptosis via caspase-3 in a mouse photoreceptor cell line. J Biol Chem 279, 35564-35572.
48. Singal PK, Iliskovic N, Li T & Kumar D (1997). Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 11, 931-936.
49. Singal PK, Li T, Kumar D, Danelisen I & Iliskovic N (2000). Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 207, 77-86.
50. Smuder AJ, Kavazis AN, Hudson MB, Nelson WB & Powers SK (2010). Oxidation enhances myofibrillar protein degradation via calpain and caspase-3. Free Radic Biol Med 49, 1152-1160.
51. Smuder AJ, Kavazis AN, Min K & Powers SK (2011). Exercise protects against doxorubicin-induced oxidative stress and proteolysis in skeletal muscle. J Appl Physiol 110, 935-942.
52. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T & Schlattner U (2006). New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol 41, 389-405.
53. vanNorren K, vanHelvoort A, Argiles JM, vanTuijl S, Arts K, Gorselink M, Laviano A, Kegler D, Haagsman HP & vander Beek EM (2009). Direct effects of doxorubicin on skeletal muscle contribute to fatigue. Br J Cancer 100, 311-314.
54. Wallace KB (2007). Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis. Cardiovasc Toxicol 7, 101-107.
55. Whidden MA, Smuder AJ, Wu M, Hudson MB, Nelson WB & Powers SK (2010). Oxidative stress is required for mechanical ventilation-induced protease activation in the diaphragm. J Appl Physiol 108, 1376-1382.
56. Wonders KY, Hydock DS, Greufe S, Schneider CM & Hayward R (2009). Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW2974. Cancer Chemother Pharmacol 64, 1105-1113.
57. Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, Obana M, Hayata N, Uozumi Y, Maeda M, Fujio Y & Azuma J (2008). Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res 79, 89-96.
58. Yen HC, Oberley TD, Vichitbandha S, Ho YS & St Clair DK (1996). The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 98, 1253-1260.
59. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW & Szeto HH (2004). Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 279, 34682-34690.